Enabled by radar technology, Xandar Kardian's XK300 system can provide continuous monitoring of motion, resting heart rate and respiratory rate of a patient.
The human body is a treasure trove of data. We constantly generate thermal heat as we burn energy, create sounds, generate electrical currents and make macro/micro motion; including nano-vibrations from inside the body. Xandar Kardian has pioneered the use of impulse UWB radar technology to safely obtain frequencies from macro body motions as we move and from micro nano-vibrations generated by our respiratory and circulatory systems.
Xandar Kardian has obtained all EMC (Electromagnetic Compatibility) and EMI (Electromagnetic Interference) safety certifications. Frequency power output is - 41.3dbM, which is equivalent to a home Wi-Fi signal, standing 40 meters (131 ft) away.
Using 6.5-8ghz impulse radio UWB radar, it detects information from our body by sending out 15 million impulse signals per seconds which is then translated into 10 data set conclusions per second (600 per minute) which is compiled to provide Body Motion Index, Respiratory Rate and Resting Heart Rate information.
Xandar Kardian’s XK300 model is the world’s first and only commercially available FDA 510(k) cleared class II medical device for non-invasive monitoring of motion, resting heart rate, respiratory rate and even presence detection of a patient using radar technology. . It is cleared for use in general hospitals, nursing homes (all categories including SNF, AL, IL, AAL, Memory Care) and also in residential homes for home health monitoring (qualifies for CPT CODE 99454, Medicare/Medicaid Reimbursement).
Detect deterioration in real-time = provide rapid proactive responses for early intervention. Monitoring of motion, resting heart rate and respiratory rate of a patient allows recognition of changes that may indicate onset of various CRD/CVD and other preventable forms of deterioration.
Provide better quality care while reducing hospitalization with early deterioration detection by using autonomous, contact-free and continuous monitoring systems like the XK300. It can also provide relief for staff from conducting redundant tasks.
Xandar Kardian’s XK300 is FDA 510(k) cleared for use as a home healthcare device for data collection to inform patient care (but not to acutely treat a patient). The device is designed to be simple to install and even easier to use by any one without special medical or technical knowledge. It’s a true “plug and play” design.
There are an estimated 92 million Americans (15 million of which are seniors) that either requires or benefit greatly from continuous RHR + RR monitoring at home.
Xandar Kardian’s XK300 may qualify for monthly reimbursement for those suffering from CRD/CVD via Medicare/Medicaid.
FDA 510(k) cleared Class II Medical Device, intended for use in general hospital, LTC facilities and residential homes for long-term health monitoring for those with chronic respiratory or cardiovascular disorders. Some patients may also qualify for reimbursement from Medicare/Medicaid (CPT CODE 99454).
Designed to detect motion or vital signs non-stop without any concern for privacy.
Automatically detects and monitors without staff intervention or patient participation.
No wearables or no special bed or chair needed. Accurately monitor RHR up to 9 ft. and RR up to 24 ft. away.
Early deterioration detection in real-time of patients in hospitals, identify at-risk residents several hours or days in advance and get automatic prioritization of patients based on deterioration levels.
Xandar Kardian’s strives to provide the highest quality, accurate, consistent measurement of vital signs to help improve quality of life and save lives. It adheres to leading security, efficacy and compliance standards to achieve this goal.
1. Al-Qahtani S, Al-Dorzi HM. Ann Thorac Med. 2010;5(1):1–4
2. Field D (2006) ‘Respiratory care’. In: Sheppard M, Wright M eds. Principles and practice of high dependency nursing 2nd edn. Bailliere Tindall, Edinburgh
3. Fieselmann JF, Hendryx MS, Helms CM, et al. Respiratory rate predicts cardiopulmonary arrest for internal medicine patients. J Gen Intern Med 1993; 8: 354-360.
4. Goldhill DR, McNarry AF, Mandersloot G, et al. A physiologically-based early warning score for ward patients: the association between score and outcome. Anaesthesia 2005; 60: 547-553
5. HealthGrades, Inc: Third Annual Patient Safety in American Hospitals Study. April 2006
6. AHA Database, 2013) , (Weinger MB and Lee La. No patient shall be harmed by opioid-induced respiratory depression. APSF Newsletter. Fall. 2011.
7. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD) Eur Respir J. 1995;8:1398–1420. doi: 10.1183/09031936.95.08081398.